Special Issue

Emerging Therapeutic Strategies for Epilepsy: Bridging Research and Clinical Practice

Message from the Guest Editor

This Special Issue is focused on advancing novel therapeutic strategies specifically for the treatment of epilepsy, a neurological disorder that remains a significant medical challenge.

We invite leading researchers and clinicians to explore breakthroughs in epilepsy treatment, including the development of novel antiseizure medications, gene therapies, and innovative techniques such as neurostimulation. The issue will highlight emerging therapeutic approaches, such as precision medicine and neuroprotective agents, which offer potential for modifying the course of the disease rather than symptomatic relief.

By addressing key mechanisms such as neuronal hyperexcitability, synaptic dysfunction, and neuroinflammation, this issue seeks to advance our understanding of epileptogenesis and novel treatment strategies. The collection aims to inspire new research directions and foster hope for improved management and care for individuals living with epilepsy.

Guest Editor

Dr. Tanveer Singh

Department of Molecular and Integrative Physiology, University of Illinois at Urbana-Champaign, Urbana, IL 60801, USA

Deadline for manuscript submissions

closed (31 October 2025)



an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/218240

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +4161 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines





an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

- Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).